J&J's real-world bladder cancer study started in HealthVerity Marketplace

Using linked claims/EHR data from HealthVerity Marketplace covering Oct 2015-Dec 2022, Johnson & Johnson analyzed 23,280 NMIBC patients and identified 1,094 who developed BCG-unresponsive carcinoma in situ. Only 486 patients (44.4%) received subsequent treatment within a year; intravesical chemotherapy was most common (45% of treated patients) but 68% of those recurred or progressed within a year (median 174 days), while radical cystectomy, the guideline-recommended approach, was used in only 25% of patients. More than half of BCG-unresponsive CIS patients received no further treatment for at least a year after recurrence, reinforcing the need for novel bladder-sparing therapies.

HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.